LIXTE Biotechnology Holdings IncLIXT noted that a team of scientists reported that in three difficult-to-treat cancer types, LIXTE’s lead compound, LB-100, combined with an inhibitor of the WEE1 kinase, causes unexpectedly effective cancer cell killing.
Most surprisingly, when cancer cells acquire resistance to this combination therapy, they have highly reduced cancer-causing capacity in animal models.
This observation indicates that LB-100 combination therapy can force cells to give up their cancer-causing properties to acquire drug resistance.
John Kovach, CEO and Founder of LIXTE and a co-author of the report, said the treatment of cancer cells with Lixte’s lead clinical compound, LB-100, rather than inhibiting, further stimulates the signals that drive cancer cell proliferation, but paradoxically, impeding cell proliferation.
Dr. Kovach continued, “The authors also show that combination of LB-100 with an inhibitor of WEE1, a regulator of stress responses in the cell, leads to highly efficient cancer cell death in three hard-to-treat cancer models: colorectal, pancreatic, and bile duct carcinomas.”
The combination of LB-100 and WEE1 inhibition suppressed the growth of patient-derived tumors refractory to conventional therapies and was associated with only modest toxicity in animal models.
Price Action: LIXT shares are up 146% at $2.00 on the last check Tuesday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
